Luis Figuero-Perez

Mr. Luis Figuero-Perez

Hospital Universitario de Salamanca
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
LFLuis Figuero-Perez
Luis Figuero-Perez
JCJuan Jesús Cruz-Hernández
Juan Jesús Cruz-Hernández
RSRogelio González Sarmiento
Rogelio González Sarmiento
Ricardo Usategui-MartínRicardo Usategui-Martín
Ricardo Usategui-Martín
JMJ. Pablo Miramonte-González
J. Pablo Miramonte-González
The dopaminergic system can adapt to the different physiological or pathological situations to which the kidneys are subjected throughout life, maintaining homeostasis of natriuresis, extracellular volume, and blood pressure levels. The role of renal dopamine receptor dysfunction is clearly established in the pathogenesis of essential hypertension. Its associations with other pathological states such as insulin resistance and redox balance have also been associated with dysfunction of the dopaminergic system. The different dopamine receptors (D1–D5) show a protective effect against hypertension and kidney disorders. It is essential to take into account the various interactions of the dopaminergic system with other elements, such as adrenergic receptors. The approach to therapeutic strategies for essential hypertension must go through the blocking of those elements that lead to renal vasoconstriction or the restoration of the normal functioning of dopamine receptors. D1-like receptors are fundamental in this role, and new therapeutic efforts should be directed to the restoration of their functioning in many patients. More studies will be needed to allow the development of drugs that can be targeted to renal dopamine receptors in the treatment of hypertension.

2 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
EBEDEL DEL BARCO-MORILLO
EDEL DEL BARCO-MORILLO
CPCarmen Parra Pérez
Carmen Parra Pérez
JMJ. Pablo Miramonte-González
J. Pablo Miramonte-González
LFLuis Figuero-Perez
Luis Figuero-Perez
MCMaría Dolores Ludeña de la Cruz
María Dolores Ludeña de la Cruz
Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.

12 February 2021 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
PDF file
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
LFLuis Figuero-Perez
Luis Figuero-Perez
MMMaría A. Amores Martín
María A. Amores Martín
LHLorena Bellido Hernández
Lorena Bellido Hernández
LMLaura Mezquita
Laura Mezquita
JHJuan Jesús Cruz Hernández
Juan Jesús Cruz Hernández
Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested as hemophagocytic syndrome (HPS), which was successfully treated with an anti-interleukin-6 antibody (tocilizumab). Case Report. This case presents a 75-year-old woman diagnosed with metastatic choroidal melanoma, refractory to several lines of treatment. After the failure of the previous lines, ipilimumab was started. After the third dose, she developed grade 2 thrombocytopenia and anemia accompanied by elevated levels of ferritin, triglycerides, and decreased fibrinogen. Hemophagocytosis was observed in the bone marrow biopsy, and a PET-CT showed splenomegaly with increased metabolism. Treatment was based on high doses of corticosteroids and tocilizumab. Four days after the start of treatment, progressive clinical and analytical improvement was observed, achieving total remission of the condition. Discussion. HPS induced by immunotherapy is due to an immunorelated cytokine storm syndrome (CSS). The administration of the anti-interleukin-6 receptor antibody drug acted on this cytokine cascade, leading to stabilization and subsequent remission. For this reason, the use of tocilizumab should be part of the immunotherapy-induced HPS treatment algorithm.

28 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ITIrene Toribio-García
Irene Toribio-García
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
JMJ. Pablo Miramonte-González
J. Pablo Miramonte-González
LPLuis Posado-Domínguez
Luis Posado-Domínguez
AGAna Martín García
Ana Martín García
EBEDEL DEL BARCO-MORILLO
EDEL DEL BARCO-MORILLO
Introduction: Immunotherapy represents a key pillar of cancer treatments, with high response rates and long survival. Its use is increasing, mainly at the expense of the geriatric population due to the ageing of this population. However, despite its benefit, its safety in certain areas such as cardiotoxicity is largely unknown. The aim of this study is to assess the safety of immunotherapy in elderly patients using real-world data. Methods: This is an ambispective study of patients ≥ 70 years old with solid tumours who were treated with immunotherapy at the University Hospital of Salamanca. Cardiotoxicity was assessed using the CTCAEv5.0 criteria. Results: In total, 195 patients were included (76.9% male and 23.1% female), with a mean age of 75 years [70–93]. The percentage of patients with cardiotoxicity was 1.54%; 1.35% of patients with previous heart disease were diagnosed with cardiotoxicity, and 1.65% of those without previous heart disease were diagnosed with cardiotoxicity. The median time from the initiation of treatment until the cardiac event was 45 days [14–96]. The most frequent toxicity was myocarditis in 66.7% of patients, followed by arrhythmias in 33.3% of patients. Conclusions: Immunotherapy is shown to be a safe treatment in elderly cancer patients in terms of cardiotoxicity. The event rate shows no difference between patients with or without cardiac comorbidity.

1 December 2021 in Reumatología Clínica
Verified
Journal Article
Closed access
LFLuis Figuero-Perez
Luis Figuero-Perez
AOAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
RERoberto A. Escala-Cornejo
Roberto A. Escala-Cornejo
ETEduardo Terán-Brage
Eduardo Terán-Brage
ÁLÁlvaro López-Gutiérrez
Álvaro López-Gutiérrez
JCJuan J. Cruz-Hernández
Juan J. Cruz-Hernández

28 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alejandro Olivares-HernándezAlejandro Olivares-Hernández
Alejandro Olivares-Hernández
LFLuis Figuero-Perez
Luis Figuero-Perez
ETEduardo Terán-Brage
Eduardo Terán-Brage
ÁLÁlvaro López-Gutiérrez
Álvaro López-Gutiérrez
AVAlvaro Tamayo Velasco
Alvaro Tamayo Velasco
JMJ. Pablo Miramonte-González
J. Pablo Miramonte-González
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.